SecBot SecBot

GMAB

GENMAB A/S
Nasdaq· Pharmaceutical Preparations· CIK 0001434265 Biotech & Drug Discovery
$51.57 +0.20 (+0.39%)
Nov 16 4:00 PM ET · prev $51.37
Market cap
$32.3B
Large cap
Consensus
Buy
80% Buy or better · 25 analysts
Median target
$65.60
+27% · range $48.00–80.00
1 year
+69.5%
from $30.42 · Nov 17
30 days
+33.9%
from $38.50
52-week range
$23.85–57.29
−10% from high · low Jun 2
Avg volume 20D
6.45M
Oct 28 spike 29.28M
Short interest
9.66M
≈1.6% of shares · +46.4%
Days to cover
1.2
at average volume
New fund stakes
3
Q3 2026 13F · 0 exits
Filing reports
31
analyzed by SecBot
SecBot read BULLISH 19 reports · 90 days
Balance 0 bearish · 3 bullish · 16 neutral oldest → newest, height = score
Avg score ·High conf. 17/19

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q3 2026: 35 added (3 new), 9 trimmed or exited. Largest new: Capital World Investors $139.2M.

  • AnalystsBULLISH

    20 of 25 rate it Buy or better. Median target $65.60 (+27%).

  • Short sellersBUILDING

    Short interest +46.4% to 9.66M shares. 1.2 days to cover, ≈1.6% of shares.

  • TrendUPTREND

    24% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 31.

Who's buying

13F· Q3 2026
3
new positions
0
exits
$139.2M
in new stakes · top 1 shown
FundMoveSharesValue
BlackRock, Inc.ADD6,057,192$216.1M
Capital World InvestorsNEW3,900,744$139.2M
RENAISSANCE TECHNOLOGIES LLCTRIM2,272,450$81.1M
MARSHALL WACE, LLPADD1,219,998$43.5M
UBS Group AGTRIM630,798$22.5M
Qube Research & Technologies LtdTRIM426,930$15.2M
Quantinno Capital Management LPADD419,368$15.0M
BNP PARIBAS FINANCIAL MARKETSADD382,677$13.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

25 analysts
Buy 80% rate it Buy or better
Strong Buy4Buy16Hold2Sell2Strong Sell1
12-month targets · 11 analysts

Price is inside the target range. Median implies +27%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 13, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Oct 30, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Oct 30, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Oct 29, 2026Truist Securities
REITERATE
REITERATEBuy
Oct 29, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 26, 2026TD Cowen
MAINTAIN
MAINTAINBuy

Short side

FINRA· Oct 30, 2026
9,659,086
shares short
+46.4%
vs prior settlement
1.2
days to cover
≈1.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Genmab filed a Form 6-K disclosing routine insider share sales by two board members. Board member Martin Schultz sold…
6-K · Impact 2/10
Nov 12, 2026 SEC
Genmab filed a Form 6-K disclosing a sale of 1,071 shares by Executive Vice President and Chief Commercial Officer…
6-K · Impact 2/10
Sep 30, 2026 Inst.
BlackRock, Inc. · ADD
6,057,192 shares ($216.1M)
Sep 30, 2026 Inst.
Capital World Investors · NEW
3,900,744 shares ($139.2M)
Sep 30, 2026 Short interest report
Short Interest: GMAB up 23% to 6.1M shares
Settlement 2026-09-30 | Days to cover: 2.09 | ≈4.72% of shares outstanding (est.)
Jun 26, 2024 Event
EPKINLY
Supplemental Approval, Efficacy, EPCORITAMAB-BYSP, INJECTABLE, SUBCUTANEOUS

Washington

Corporate Lobbying

18 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

SecBot reports

31 filings · 6 bullish · 1 bearish · 24 neutral
All GMAB filing & press-release reports (31)